KB-1343

9D9-mIgG2b

Home » Antibody » 9D9-mIgG2b

Background

9D9 antibody is specific for mouse CTLA-4. The antibody has been used to block CTLA-4 and has been shown to enhance T-cell immunity against tumours. 9D9 also has an anti-B16/BL6 melanoma effect in non-irradiated tumour-bearing recipients when given as combinatorial therapy with Gvax. This mechanism both involves blockade of CTLA4 as well as depletion of tumor-infiltrating regulatory T-cells. Fc Silent antibodies were shown to have reduced anti-tumor activity as they did not deplete tumor infiltrating regulatory T-cells, however they lead to expansion of peripheral Tregs.

Specifications

Catalog Number:
KB-1343
Cell Line Name:
9D9-mIgG2b
Price:
0
Host Cell Line:
EXPI-CHO
Target:
Mouse-CTLA4
Species Reactivity:
Mouse
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 2006;90:297¨C339. doi: 10.1016/S0065-2776(06)90008-X. 2.Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734¨C1736.
Please enable JavaScript in your browser to complete this form.